Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABBV 154

Next Previous
X
Search
Drug Profile

ABBV 154

Alternative Names: ABBV-154

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Anti-inflammatories; Antirheumatics; Drug conjugates; Immunoconjugates; Steroids
  • Mechanism of Action Glucocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Polymyalgia rheumatica
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Aug 2023 AbbVie terminates a phase II trial in Rheumatoid arthritis (Treatment-experienced) in USA, Ukraine, Turkey, Taiwan, Spain, Slovakia, Russia, Poland, Puerto Rico, New Zealand, Netherlands, South Korea, Japan, Italy, Israel, Hungary, Greece, Germany, Czech Republic, Canada and Australia (SC) due to business decision (NCT04888585)
  • 24 Jul 2023 Abbvie terminates a phase II (AIM-PMR) trial in Polymyalgia rheumatica (Treatment-experienced) in US, Australia, Austria, Canada, France, Germany, Hungary, Italy, Japan, South Korea, Netherlands, New Zealand, Poland, Spain, United Kingdom (SC) due to business decision (EudraCT2021-000648-23) (NCT04972968)
  • 20 Jul 2023 AbbVie terminates a Phase-II clinical trials in Crohn's disease in Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Slovakia, South Korea, Spain, Taiwan, Turkey, United Kingdom, USA(SC) due to strategic considerations (NCT05068284)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top